https://orcid.org/0000-0002-2175-5117
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The disposition of a novel kynurenine monooxygenase inhibitor, CHDI-340246, was investigated in vitro and in animals.
In vitro, there was minimal metabolic turnover of CHDI-340246 in all species. The protein binding was higher in human plasma (99.7%) relative to other species.
In all species, blood clearance was low (<20% of liver blood flow) and volume of distribution was small (<0.5 L/kg). The terminal half-life was longer in monkeys (9 hr) than in mice, rats, or dogs (1–2 hr). CHDI-340246 was orally bioavailable (>60%) in all species.
In rats, [14C]CHDI-340246 showed wide distribution of radioactivity in all tissues except brain and testes. In rats, the parent drug was the major circulating moiety with minor amounts of a sulphate conjugate of an O-dealkylated metabolite. The elimination occurred via the urinary route and to a lesser extent by biliary route, but mostly as metabolites. In cynomolgus monkeys, the parent drug predominated in plasma with only trace amounts of metabolites detected.
Acyl glucuronide conjugate of CHDI-340246 was not detected in plasma of rats or monkeys.
Overall, the ADME profile of CHDI-340246 was favourable in rats and monkeys for potential evaluation of KMO inhibition in humans.
Acknowledgments
This work was funded by CHDI Foundation (https://chdifoundation.org/) whose sole mission is to accelerate therapeutic development for Huntington's D disease. V. Khetarpal, T. Herbst, I. Munoz-Sanjuan, and C. Dominguez are employees of CHDI Management that supports CHDI Foundation. All studies were conducted by contract research organizations (CROs) under fee-for-service agreements.
Disclosure statement
No potential conflict of interest was reported by the author(s).